TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03093701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC399 (ProDex)
Description: 2-vial system: TLC399-DSP and TLC399-Lipid
Study: NCT01207310

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation counseling
Description: two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
Study: NCT05082415

Intervention type: DRUG
Intervention: Brolucizumab
Description: Participants received brolucizumab injection during the index period
Study: NCT04193774

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Conjunctival swab
Description: Swab of the conjunctival fornices of both eyes

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conjunctival swab
Description: Swab of the conjunctival fornices of both eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybuprocaine Hydrochloride 0.4% Eye Drops
Description: One drop of topical anesthesia in one eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artificial tears
Description: One drop of artificial tears in the other eye
Study: NCT02968147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation
Description: General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional ventilation
Description: General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
Study: NCT02924909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin paclitaxel
Description: induction carboplatin paclitaxel for 2 cycles
Study: NCT00254891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676 + Paclitaxel + Carboplatin
Description: * PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Carboplatin
Description: * Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles.
Study: NCT01879969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: classic procedure of planning
Description: analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer assisted orthognathic planning and surgery of asymmetric patients
Study: NCT03083145

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Beverage
Description: Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Beverage
Description: Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pea Protein Beverage
Description: Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
Study: NCT02183220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA placebo
Study: NCT02102776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAG
Description: A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
Study: NCT03083145

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pea Protein Beverage
Description: Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snack Tray Choices
Description: Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snack Tray Choices
Description: Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
Study: NCT04108806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Ballon dialtation of the diseased artery
Study: NCT02023047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 12 mg coated suppositories

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 12 mg coated suppositories
Study: NCT02516228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTEN 100
Description: Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days.
Study: NCT00154882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Phyxol) , Cisplatin
Study: NCT02736981

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BWL + Autonomous Motivation
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BWL + Extrinsic Motivation
Description: The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
Study: NCT03189836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTR707
Description: autologous T cell product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: CD20-directed cytolytic antibody
Study: NCT03368235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567
Description: oral OD SGRM administered as suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: oral capsules of 20 mg prednisolone administered OD for two weeks
Study: NCT03932630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balanced diet
Description: The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
Study: NCT01207310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Description: two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 8 weeks' worth of nicotine patches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 8 weeks' worth of nicotine patches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alphanumeric pager
Description: therapeutic messages to be delivered for three months
Study: NCT02012270

Intervention type: PROCEDURE
Intervention: PRINCIPLES technique
Description: Principles technique for closure of midline laparotomy incisions~* closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~* the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~* the SL/WL ratio should be at least 4/1~* SL/WL = (150cm x number of sutures used) - (the suture remnants)~* the mean stitch length should be less than 4 cm (suture length / number of stitches placed)

Intervention type: PROCEDURE
Intervention: Conventional group
Description: the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
Study: NCT01238107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-102
Description: BETA BLOCKER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-102
Description: BETA BLOCKER

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT-102
Description: BETA BLOCKER
Study: NCT04052620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac diethylamine 2.32% gel
Description: Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 1.16% gel
Description: Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Study: NCT03649984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Navi© Program
Description: Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
Study: NCT04496518

Intervention type: DEVICE
Intervention: Intrinsic Antitachycardia Pacing (iATP) Therapy
Description: iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
Study: NCT04387942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
Study: NCT02966977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional microbiological identification by culture plate
Description: Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional microbiological identification by culture plate
Description: Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct mass spectrometry identification from urine sample
Description: The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
Study: NCT02478879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP-PTH
Description: Patch applied daily for 30 minutes, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FORTEO
Description: Subcutaneous injection administration daily for 14 days
Study: NCT00390637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High or low Glycemic Index and high or low Protein Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High or low Glycemic Index and high or low Protein Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High or low Glycemic Index and high or low Protein Diet
Study: NCT02237937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study: NCT00390637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High or low Glycemic Index and high or low Protein Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High or low Glycemic Index and high or low Protein Diet
Study: NCT03334461

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exposure to oral antiseptics or enamel remineralisation agent

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exposure to oral antiseptics or enamel remineralisation agent
Study: NCT04775303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.1% (Ikervis®) eye drop
Description: One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
Study: NCT03077139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
Study: NCT01153373

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.
Description: All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse
Description: All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
Study: NCT03993379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: CX-072 in combination with ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: CX-072 in combination with ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: CX-072 in combination with ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: CX-072 in combination with ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CX-072 in combination with ipilimumab
Study: NCT02308995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy using barbed sutures
Description: A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy using conventional sutures
Description: A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Loc (Covidien, Mansfield, MA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)
Study: NCT03900455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocellular polyurethane foam multilayer dressing
Description: Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard preventive care
Description: Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard preventive care
Description: Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
Study: NCT01256879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: cimetidine
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: cimetidine
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: cimetidine
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: cimetidine
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
Study: NCT01679652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Tablet i blinded in capsula

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo